Previous close | 215.70 |
Open | 216.00 |
Bid | 217.80 x N/A |
Ask | 219.50 x N/A |
Day's range | 216.00 - 218.60 |
52-week range | 205.90 - 261.00 |
Volume | |
Avg. volume | 1 |
Market cap | 63.177B |
Beta (5Y monthly) | 0.46 |
PE ratio (TTM) | 50.02 |
EPS (TTM) | 4.37 |
Earnings date | 02 May 2024 |
Forward dividend & yield | 3.53 (1.62%) |
Ex-dividend date | 10 Jun 2024 |
1y target est | N/A |
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: